Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M., & Osborne, C. K. (1992) · Breast Cancer Research and Treatment · doi:10.1007/bf01961241 · Cited by 750
Cited by
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citationTrastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Targeting HER2-positive breast cancer: advances and future directions
Swain, S. M., Shastry, M., & Hamilton, E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00579-0 · Cited by 1,160
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Chu, T. F., Rupnick, M. A., Kerkela, R., Dallabrida, S. M., Zurakowski, D., Nguyen, L., Woulfe, K., Pravda, E., Cassiola, F., Desai, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61865-0 · Cited by 1,083
Mechanisms of drug combinations: interaction and network perspectives
Jia, J., Zhu, F., Ma, X., Cao, Z. W., Li, Y. X., & Chen, Y. Z. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2683 · Cited by 969
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
Nahta, R., Yu, D., Hung, M.-C., Hortobagyi, G. N., & Esteva, F. J. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0509 · Cited by 916
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 882
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00097-1 · Cited by 873
“This dose response relationship is similar to that reported with trastuzumab and the ErbB2-transfected MCF7 cell line (Pietras et al., 1998).”
ResultImproving the efficacy of antibody-based cancer therapies
Carter, P. (2001) · Nature Reviews Cancer · doi:10.1038/35101072 · Cited by 833
von Minckwitz, G., du Bois, A., Schmidt, M., Maass, N., Cufer, T., de Jongh, F. E., Maartense, E., Zielinski, C., Kaufmann, M., Bauer, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6618 · Cited by 676
STAT proteins: novel molecular targets for cancer drug discovery
Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1204086 · Cited by 643
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
Harari, D., & Yarden, Y. (2000) · Oncogene · doi:10.1038/sj.onc.1203973 · Cited by 633
Seidman, A. D., Fornier, M. N., Esteva, F. J., Tan, L., Kaptain, S., Bach, A., Panageas, K. S., Arroyo, C., Valero, V., Currie, V., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2587 · Cited by 547
Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis
Li, Y. M., Pan, Y., Wei, Y., Cheng, X., Zhou, B. P., Tan, M., Zhou, X., Xia, W., Hortobagyi, G. N., Yu, D., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.027 · Cited by 537
Pegram, M. D., Konecny, G. E., O'Callaghan, C., Beryt, M., Pietras, R., & Slamon, D. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh131 · Cited by 512
Self-citationSpector, N. L., & Blackwell, K. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1507 · Cited by 497
Robert, N., Leyland-Jones, B., Asmar, L., Belt, R., Ilegbodu, D., Loesch, D., Raju, R., Valentine, E., Sayre, R., Cobleigh, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.1764 · Cited by 479
Self-citationHerceptin: mechanisms of action and resistance
Nahta, R., & Esteva, F. J. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.01.041 · Cited by 446
Overexpression of ErbB2 in cancer and ErbB2-targeting strategies
Yu, D., & Hung, M.-C. (2000) · Oncogene · doi:10.1038/sj.onc.1203972 · Cited by 430
Burstein, H. J., Kuter, I., Campos, S. M., Gelman, R. S., Tribou, L., Parker, L. M., Manola, J., Younger, J., Matulonis, U., Bunnell, C. A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2722 · Cited by 366
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
Normanno, N., Bianco, C., De Luca, A., Maiello, M. R., & Salomon, D. S. (2003) · Endocrine-related cancer · doi:10.1677/erc.0.0100001 · Cited by 336
Her-2 Overexpression Increases the Metastatic Outgrowth of Breast Cancer Cells in the Brain
Palmieri, D., Bronder, J. L., Herring, J. M., Yoneda, T., Weil, R. J., Stark, A. M., Kurek, R., Vega-Valle, E., Feigenbaum, L., Halverson, D., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3316 · Cited by 333
Trastuzumab in the Treatment of Breast Cancer
Hortobagyi, G. N. (2005) · New England Journal of Medicine · doi:10.1056/nejme058196 · Cited by 306
Pegram, M. D., Pienkowski, T., Northfelt, D. W., Eiermann, W., Patel, R., Fumoleau, P., Quan, E., Crown, J., Toppmeyer, D., Smylie, M., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh133 · Cited by 271
Self-citationTargeting HER2 for the Treatment of Breast Cancer
Rimawi, M. F., Schiff, R., & Osborne, C. K. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-042513-015127 · Cited by 268
Friedman, L. M., Rinon, A., Schechter, B., Lyass, L., Lavi, S., Bacus, S. S., Sela, M., & Yarden, Y. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409610102 · Cited by 252
Ithimakin, S., Day, K. C., Malik, F., Zen, Q., Dawsey, S. J., Bersano-Begey, T. F., Quraishi, A. A., Ignatoski, K. W., Daignault, S., Davis, A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3349 · Cited by 236
The role of overexpressed HER2 in transformation
Neve, R. M., Lane, H. A., & Hynes, N. E. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_1.s9 · Cited by 173
“The specific factors that induce amplification of the HER2 gene have yet to be fully elucidated [20].”
BackgroundHerceptin: From the Bench to the Clinic
Colomer, R., Shamon, L. A., Tsai, M. S., & Lupu, R. (2001) · Cancer Investigation · doi:10.1081/cnv-100000074 · Cited by 43
Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies
Mo, C., Sterpi, M., Jeon, H., & Bteich, F. (2024) · Cancers · doi:10.3390/cancers16162854 · Cited by 8
(2001) · PubMed
Metadata
- Authors
- Pietras, R. J., Pegram, M. D., Finn, R. S., Maneval, D. A., & Slamon, D. J.
- Venue
- Oncogene
- Published
- 1998-10-29
- Volume
- 17
- Issue
- 17
- Pages
- 2235-2249
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2019895529
- Cited by
- 386
- References
- 1
- FWCI
- 9.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.